CHEK2 and Unclassified Renal Cell Carcinoma: Of the remaining 28 (45%) uRCC, 8 cases carried mutations of genes involved in chromatin modulation (SETD2, BAP1, KMT2A/C/D and PBRM1); 5 in DNA damage response (TP53, CHEK2 and BRCA2); and 15 without recurrent molecular features based on our analyses (Fig. 4a).